Physician profile
Behzod Rostam
NPI 1902125677
$30,139.35
in general payments reported to CMS, 2019-2025
35 companies · $995 in 2025
The $995 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $857 · 2020: $467 · 2021: $15K · 2022: $10K · 2023: $1,191 · 2024: $1,107 · 2025: $995.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,293.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,293.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $24,848.95 | 2019-2025 | Krystexxa, Otezla, Repatha |
| Abbvie INC. | $778.64 | 2021-2025 | Vraylar |
| Horizon Therapeutics Plc | $683.20 | 2020-2023 | Krystexxa |
| Lilly USA, LLC | $441.52 | 2019-2024 | Mounjaro, Jardiance, Zepbound |
| Axsome Therapeutics, INC. | $424.16 | 2023-2024 | Auvelity |
| Novo Nordisk INC | $419.00 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Esperion Therapeutics, INC. | $321.87 | 2020-2025 | Nexletol |
| Astrazeneca Pharmaceuticals LP | $284.55 | 2019-2025 | Airsupra, Breztri |
| Corium, LLC | $259.41 | 2022-2024 | Azstarys, Azstarys |
| Boehringer Ingelheim Pharmaceuticals, INC. | $257.68 | 2019-2024 | Stiolto Respimat, Spiriva Respimat |
| Mimedx Group, INC. | $170.41 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $157.87 | 2019-2024 | |
| Mylan Specialty L.P. | $133.80 | 2020-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $118.94 | 2022-2025 | Caplyta |
| Glaxosmithkline, LLC. | $103.89 | 2019-2025 | Trelegy Ellipta |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $92.96 | 2019-2021 | |
| Ironshore Pharmaceuticals INC. | $74.92 | 2023-2024 | Jornay Pm |
| Otsuka America Pharmaceutical, INC. | $68.67 | 2020-2024 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $68.35 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $57.67 | 2023-2025 | Qelbree, Qelbree |
| Novartis Pharmaceuticals Corporation | $50.71 | 2021-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $45.27 | 2021-2025 | Entyvio |
| Allergan, INC. | $39.74 | 2020 | |
| Verona Pharma, INC. | $38.51 | 2025 | Ohtuvayre |
| Xeris Pharmaceuticals, INC. | $38.28 | 2024-2025 | Gvoke Hypopen |
| Exact Sciences Corporation | $23.08 | 2024 | Cologuard Collection Kit |
| Philips North America LLC | $21.19 | 2025 | Diagnostic Ecg Service |
| Vanda Pharmaceuticals INC. | $17.96 | 2024 | Fanapt |
| Bioventus LLC | $15.88 | 2020 | |
| Idorsia Pharmaceuticals US INC | $15.49 | 2023 | Quviviq |
| Baxter Healthcare | $13.95 | 2024 | Hillrom - Vest System Model 105 Home Care |
| Janssen Pharmaceuticals, INC | $13.84 | 2022 | |
| Alkermes, INC. | $13.46 | 2022 | |
| Dexcom, INC. | $13.41 | 2024 | Dexcom G6 Transmitter |
| Radius Health, INC. | $12.12 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Behzod Rostam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.